To view the causes of familial adenomatous polyposis (FAP), click here
To view the causes of hereditary nonpolyposis colorectal cancer (HNPCC), click here
Colorectal cancer has no single cause. It develops through a stepwise build-up of genetic and epigenetic changes that turn normal colonic epithelium into adenocarcinoma, usually over 10–15 years.[1] Three overlapping molecular pathways account for nearly all cases:
the chromosomal instability (CIN) pathway
the mismatch repair–deficient/microsatellite instability (dMMR/MSI) pathway
the serrated neoplasia pathway, which is linked to BRAF mutation and the CpG island methylator phenotype (CIMP)[2][3]
Germline defects in these same pathways cause the hereditary colorectal cancer syndromes. The best known are Lynch syndrome (germline mismatch repair genes) and familial adenomatous polyposis (germline APC).[4][5]
The pathway a tumor follows has clinical consequences. It determines:
tumor location and precursor lesion type
microsatellite status
whether an MSI-high tumor is sporadic or Lynch-associated[2][6]
The three pathways differ in the type of genomic instability and the precursor lesion.[2][3][1] The proportions below overlap and add up to more than 100%. This is because serrated-pathway tumors can become either MSI-high (through MLH1 methylation) or microsatellite-stable.[5]
Principal molecular pathways of colorectal carcinogenesis
This is the classic adenoma–carcinoma sequence and the most common route to CRC.[3][7]
Initiation: biallelic loss of the APC tumor suppressor (or, less often, an activating CTNNB1/β-catenin mutation) switches on WNT/β-catenin signaling without control. The first visible lesion is the aberrant crypt focus.[3][7][2]
Progression: changes then accumulate in order: adenoma: KRAS or NRAS and PIK3CA mutations, and loss of heterozygosity at 18q (SMAD4/DCC) invasive carcinoma: TP53 mutation marks the transition.[3][9][10]
CIN tumors are usually MSS, occur more often in the left colon and rectum, and fall mainly into consensus molecular subtypes CMS2–CMS4.[3]
Cause: loss of DNA mismatch repair genes (MLH1, MSH2, MSH6, PMS2). This happens in one of two ways: germline: a pathogenic variant (Lynch syndrome) sporadic (more common): somatic MLH1 promoter hypermethylation.[3][7][6]
Consequence: a hypermutated tumor. Frameshift mutations build up in genes that contain coding microsatellites, such as TGFBR2, ACVR2A and BAX, and speed up progression.[4]
MSH2-associated tumors usually carry somatic APC mutations (75% vs 11% in MLH1-associated tumors).
MLH1-associated tumors more often carry somatic CTNNB1 mutations (50% vs 7%).
"Shortcut" carcinogenesis in MLH1 carriers: some of these cancers may arise directly from MMR-deficient crypts without a visible polyp stage. One proposed model is a "two-in-one hit": a single event (mitotic recombination on chromosome 3p) both inactivates the remaining MLH1 allele and activates CTNNB1.[12][6]
Most common hereditary CRC syndrome; autosomal dominant constitutional MMR deficiency.[6][4] 10-year CRC risk under surveillance is similar in MLH1 and MSH2 carriers (11.3% vs 11.4%) and lower in MSH6 carriers (4.7%). MSH2 carriers have a higher 10-year risk of advanced adenoma than MLH1 carriers (17.8% vs 7.7%).[11]
MSI-high status alone does not establish Lynch syndrome. Most sporadic MSI-high CRCs arise through the serrated pathway, via somatic MLH1 promoter methylation, and carry BRAF V600E.[2][6] MSI-high tumors that are BRAF wild-type and lack MLH1 methylation suggest a germline MMR cause.[2][6]
The inflammatory tumor microenvironment, made up of immune cells, stromal cells and the intestinal microbiome, shapes colorectal tumorigenesis.[9][10] How much the microbiome and inflammation contribute to starting the CIN pathway versus the serrated pathway is not well established.[10]
The exact mechanism of adenoma-skipping ("shortcut") carcinogenesis in MLH1-associated Lynch syndrome is not fully defined. It is relevant to why colonoscopic surveillance may protect MLH1 carriers less well.[12][6]
No single standardized marker panel defines CIMP across studies, which makes studies hard to compare.[2]
↑ 7.07.17.27.37.4Lizarbe MA, Calle-Espinosa J, Fernández-Lizarbe E, Fernández-Lizarbe S, Robles MÁ, Olmo N, Turnay J (2017). "Colorectal cancer: from the genetic model to posttranscriptional regulation by noncoding RNAs". Biomed Res Int. 2017: 7354260. doi:10.1155/2017/7354260. PMID28573140.CS1 maint: Multiple names: authors list (link)
↑ 8.08.18.28.3IJspeert JE, Vermeulen L, Meijer GA, Dekker E (2015). "Serrated neoplasia—role in colorectal carcinogenesis and clinical implications". Nat Rev Gastroenterol Hepatol. 12 (7): 401–409. doi:10.1038/nrgastro.2015.73.CS1 maint: Multiple names: authors list (link)
↑ 9.09.1Schmitt M, Greten FR (2021). "The inflammatory pathogenesis of colorectal cancer". Nat Rev Immunol. 21 (10): 653–667. doi:10.1038/s41577-021-00534-x.
↑ 10.010.110.210.310.410.5Permain J, Hock B, Eglinton T, Purcell R (2024). "Functional links between the microbiome and the molecular pathways of colorectal carcinogenesis". Cancer Metastasis Rev. 43 (4): 1463–1474. doi:10.1007/s10555-024-10215-5.CS1 maint: Multiple names: authors list (link)
↑ 11.011.1Engel C, Ahadova A, Seppälä TT; et al. (2020). "Associations of pathogenic variants in MLH1, MSH2, and MSH6 with risk of colorectal adenomas and tumors and with somatic mutations in patients with Lynch syndrome". Gastroenterology. 158 (5): 1326–1333. doi:10.1053/j.gastro.2019.12.032. PMID31926173.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
↑ 12.012.1Ahadova A, Stenzinger A, Seppälä T, Hüneburg R, Kloor M, Bläker H; Lynpath Investigators (2023). "A "two-in-one hit" model of shortcut carcinogenesis in MLH1 Lynch syndrome carriers". Gastroenterology. 165 (1): 267–270.e4. doi:10.1053/j.gastro.2023.03.007. PMID36907525Check |pmid= value (help).CS1 maint: Multiple names: authors list (link)
↑He X, Wu K, Ogino S; et al. (2018). "Association between risk factors for colorectal cancer and risk of serrated polyps and conventional adenomas". Gastroenterology. 155 (2): 355–373.e18. doi:10.1053/j.gastro.2018.04.019.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
↑ 14.014.1Sommer AK, Te Paske IBAW, Jansen EAM; et al. (2026). "Mutational landscape of colorectal tumors from individuals with unexplained adenomatous or serrated colorectal polyposis". Gastroenterology. 170 (3): 557–568. doi:10.1053/j.gastro.2025.10.011.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)